07-07-2022 09:43 AM | Source: Accord Fintech
Lupin receives EIR from USFDA for Somerset Manufacturing Plant
Lupin has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
Latest News
Buy Clean Science and Technology Ltd For Target Rs.1...
Buy Somany Ceramics Ltd For Target Rs.950 By JM Fin...
Buy Gold Above 72200 SL BELOW 71900 TGT 72550/72800 ...
Indian startups raised nearly $7 billion in first ha...
Committed to learning from India how to make AI more...
World Bank classifies Mongolia as upper middle incom...
Government`s focus on non-polluting energy sources t...
Madhya Pradesh Finance Minister Jagdish Devda to pre...
Accounting firm RSM's US arm plans to more than doub...
Buy Bharti Airtel Ltd For Target Rs. 1,480 By JM Fin...